Special Issue "Personalized Therapy and Clinical Outcomes for Congenital and Acquired Haemorrhagic Disorders, Thromboembolic Disease and Platelet Disorders"
A special issue of Hematology Reports (ISSN 2038-8330).
Deadline for manuscript submissions: 8 April 2024 | Viewed by 9660
Interests: hemophilia A and B; Von Willebrand disease; rare coagulation disorders; antipholipid antibodies (lupus anticoagulant, anticardiolipin antibodies); deep vein thrombosis and pulmonary embolism; venous thromboembolism; arterial thrombosis
Special Issues, Collections and Topics in MDPI journals
In recent years, several new drugs have been developed for the treatment of bleeding disorders, particularly in haemophilic patients. Recombinant coagulation factor concentrates FVIII / FIX extended half-life and new subcutaneous hemostatic agents are available. These innovative approaches have the advantage of being able to customize therapy based on the patient's hemorrhagic phenotype and pharmacokinetics. Even in patients with deep vein thrombosis and pulmonary embolism, the new oral anticoagulants have changed the management of these patients in both acute and long-term treatment. Advances in pharmacology have significantly influenced thrombotic outcomes, but a detailed assessment of the impact of non-thrombotic diseases on haemostasis and thrombosis is needed to better assess thrombotic risk and establish optimal treatment. Recent advances in our understanding of pathogenesis and diagnosis and new therapies for inherited and acquired platelet disorders have changed our approach in these patients as well.
This special issue aims to collect and publish original research articles and reviews demonstrating recent advance in our knowledge on new diagnostic and therapeutic approaches in these clinical conditions with particular regard to the personalization of the patient's treatment on the basis of his clinical characteristics, comorbidities and preference.
Dr. Ezio Zanon
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Willebrand disease
- venous thromboembolism
- deep vein thrombosis
- pulmonary embolism
- risk factors
- inherited platelet disorders
- oral anticoagulant